Effect of Adjuvant Chemotherapy is Responsible for Decreasing Segmental and Total BMD in BC Postmenopausal Women

Bone cancer (BC), which forms in tubes and lobules of bone apkins, occurs in both men and women, although manly bone cancer is rare. It's the most common cause of cancer death among women worldwide; its prevalence rates being high in advanced countries whereas rates in developing countries and in Japan are low but adding. BC accounts for37.6 of all reported excrescences in Egyptian ladies, with an age- acclimated prevalence rate of49.6 per,000 ladies. BC, prostate cancer, and multiple myeloma have particularly shown strong association with cadaverous metastases and related bone loss, performing in fracture, hypercalcemia, pain, and declines in mobility and performance status .

Bone Cancer (BC), which forms in tubes and lobules of bone apkins, occurs in both men and women, although manly bone cancer is rare (1). It's the most common cause of cancer death among women worldwide; its prevalence rates being high in advanced countries whereas rates in developing countries and in Japan are low but adding. BC accounts for37.6 of all reported excrescences in Egyptian ladies, with an age- acclimated prevalence rate of49.6 per,000 ladies (2). BC, prostate cancer, and multiple myeloma have particularly shown strong association with cadaverous metastases and related bone loss, performing in fracture, hypercalcemia, pain, and declines in mobility and performance status (4).

Although adjuvant chemotherapy represents a significant advance in the operation of cases with BC, which has dragged their survival by dwindling the systemic relapse, it causes a significant reduction in their bone mineral viscosity (BMD) (2). therefore, women with BC are at increased threat for the development of osteoporosis and cadaverous fractures, giving rise to significant morbidity and some mortality (3), as a consequence of aromatase inhibition or chemotherapyinduced ovarian failure (5). Exemestane and anastrozole, two chemotherapeutic aromatase impediments, have been shown to directly inhibit osteoclast isolation and bone resoption labels leading to osteoporosis in postmenopausal women withnon-metastatic bone cancer (NMBC) (6). The bone resorptioncross-linked carboxytelopeptide of collagen type I (CTx- I) combined with BMD measures, can be used for assessing bone health status in postmenopausal women (8).The objects of this study were to probe biochemical labels of bone

conformation and resorption as well as segmental and total BMD in NMBC postmenopausal Egyptian women ahead and after entering a 6- cycles adjuvant chemotherapy treatment protocol.

Cases and material
The study population was comprised of 100 postmenopausal women (mean age (± SD)55.06 ±4.78 time and body mass indicator (BMI)38.28 ±4.13 kg/ m2) with recently diagnosed T1- 3 N0- 2 M0 BC, who were studied longitudinally ahead and after entering 6- cycles of a three- medicine combination protocol containing Cyclophosphamide (600 mg/ m2), Adriamycin (40 mg/ m2), and 5-

Fluoruoracil (600 mg/ m2) (CAF), as detailed away (10). Actors were signed from the Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt; where they were rehabilitated for opinion and/ or treatment; and were appertained to the Medical Biophysics and Chemical Pathology Departments, Medical Research Institute, Alexandria University, Alexandria, Egypt for posterior bone densitometric measures and blood biochemical analysis, independently. The study was conducted in agreement with ethical guidelines of the 1975 protestation of Helsinki and the Ethics Committee of the Medical Research Institute, Alexandria University approved the study protocol.

All party women were asked to freely bestow to the study protocol and handed an inked informed concurrence previous to their registration.

Clinical staging of BC was carried out according to the recent guidelines of the AJCC on base of a detailed physical examination, imaging studies, operative findings and pathologic examination of the bone and other apkins (11). Rejection criteria from the study protocol were the following (1) serum creatinine lesser than 150 mmol/ L;( 2) peptic ulcer;(3) hysterectomy or bilateral oophorectomy;( 4) osteoporosis;( 5) undressed hypothyreosis;(6) bisphosphonate, calcitonin or peroral steroid remedy;(7) gestation or lactation; and (8) other malice.

All party women were canvassed regarding general health, bone pangs, history of fractures, specifics, and menopausal status and were subordinated to a complete physical examination stressing on bone, joints, and neurological examination. The following analyses were carried out, using standard styles.

Blood biochemical analyses
Fasting blood samples were collected from all party women to determine serum situations of erythrocyte sedimentation rate( ESR, mm/ hr)( 12) and total calcium( Ca, mg/ dl)( 13) using a semi-automatic chemical analyzer( Olympus AU 400, Olympus Life and Material Science, Europe GmbH, Hamburg, Germany); osteocalcin( OC, ng/ ml)( 14), 25- hydroxyvitamin D( 25- VitD, pg/ ml)( 15), parathyroid hormone( PTH, pg/ ml)( 16) and excrescence marker CA15- 3( U/ ml)( 17) by chemiluminescence fashion( Immulite 1000, Siemens Healthcare DiagnosticsInc., Flanders, NJ, USA); and total alkaline phosphatase( peak, U/ l), bone specific alkaline

phosphatase(S.ALP, μg/ L)( 16) and carboxytelopeptide of collagen type I( CTx- I, ng/ ml)( 18) by ELISA fashion( ELISA ELx 800,Bio-Tek InstrumentsInc., Winooski, UT, USA).

Imaging, body- composition and bone densitometric measures Imaging studies were carried out for all party women using casketX-ray, abdominal and pelvic ultrasound and mammography. Demographic and body- composition variables were also measured for all party women. Specifically, body weight (kg)(actors clothed in undergarments, bare bases) was measured using a digital scale sensitive to the nearest0.01 kg( Electronic Body Scale, TCS – 200 – RT, China). Height (m) was measured using a stadiometer. Segmental (i.e., head, arms, box, caricatures, chine, pelvis and legs) and total bone mineral content (BMC) and BMD, as well as fat mass (FM), spare bone-free mass (LBFM) and towel bone-free mass (TBFM) were assessed using a Binary- energyX-ray Absorptiometry (DXA) total body scanner (Lunar DXP Pro, GE Health Care, USA), as detailed before by our group (19- 22).

Statistical analysis

Data analysis was carried out using the StatView ® statistical software package (SAS InstituteInc., Cary, NC, USA). Descriptive statistics were calculated for the mean ± SD of all applicable variables and their frequence distributions were examined. Analysis of the nonstop variables showed them to be typically distributed. Paired Student's t- test of significance was used to compare differences before and after adjuvant chemotherapy for colorful variables. Differences were considered to be significant only if p values were lower than0.05. likewise, multivariate direct retrogression analysis was performed to examine the interrelations among demographic variables and segmental and total BMD for NMBC women using simple and partial correlation portions. vaticination equations grounded on two independent variables (i.e., Age and BMI) were developed and their accretive correlation portions (R) and standard error of estimation (SEE) were calculated, as detailed away (22).

Segmental and total BMC and BMD, accordingly, total T- and Z- Scores, were all significantly (p<0>

Osteoporosis is a global public health concern presently affecting further than 200 million people worldwide, about 80 of them are women (23). Not only cases with cancer may be at threat for primary osteoporosis, but also for secondary osteoporosis due to cancer curatives; which may alter the gonadal function and negatively affect bone development (24- 27). BMD testing is considered largely effective for establishing an opinion of osteoporosis and covering its progression, since an inverse relationship exists between BMD and unborn fracture threat. BMD is expressed as a T- or Z- Score, which are the standard divagation of BMD from the anticipated BMD for a youthful grown-up or an age- matched normal population of the same Coitus, independently.
Although, data of body- composition (i.e., FM, LBFM, and TBFM) were similar before and after chemotherapy segmental and total BMC and BMD distribution were significantly (p<0>

Biochemical analysis showed that, albeit similar situations of serum Ca and 25- VitD, both peak andS.ALP were significantly lower after chemotherapy as compared to their original situations before chemotherapy. CTx- I situations were also significantly lower after chemotherapy, denoting a condition of dropped bone resorption inpost-chemotherapy NMBC women Although both labels of bone conformation and resorption were significantly lower after chemotherapy as compared to their situations before chemotherapy, accordingly denoting a lower bone development exertion, which was substantiated by the significantly lower segmental and total BMD for postchemotherapy NMBC women In line with this, Greep etal.,( 25) preliminarily reported that postmenopausal women with early BC who entered adjuvant chemotherapy had lower BMD in comparison with their counterparts who didn't admit any chemotherapy. also, Rodríguez- Rodríguez et.al.,(1), had also preliminarily detected significant diminishments in BMD at lumbar, trochanter, intertrochanter and total hipsterism after adjuvant treatment for NMBC women. The significantly advanced PTH situations after chemotherapy (i.e.,86.34 ±35.02vs.59.50 ±27.01 pg/ ml for that before chemotherapy, p<0>

The use of labels of bone development for covering bone metastases in BC and in response to remedy had been shown before (28- 30). Chemotherapeutic aromatase impediments (e.g., exemestane and anastrozole) have been shown to directly inhibit osteoclast isolation and bone resoption labels leading to osteoporosis in postmenopausal women with early BC (6), yet with supposedly increased bone resorption biochemical labels, as also had been shown before (32). It has been shown that osteoporotic bone loss and bone metastasis eventually partake a pathophysiologic pathway that stimulates bone resorption by adding the conformation and exertion of osteoclasts (4). Osteolytic lesions generally seen in BC can beget severe pain, pathologic fracture, and contraction runs of the whim-whams root or spinal cord, as well as metabolic disturbances (e.g., hypercalcemia, phosphate imbalances, dislocations in acid/ base and neurological homeostasis, and nephrolithiasis) (33). Combined osteolytic and osteoblastic lesions, which beget increased bone resorption through osteoclasts within osteoblastic lesions and compensatory, secondary bone conformation through osteoblasts within osteolytic lesions, have been observed in BC cases (34). thus, it's advised that women with BC who are witnessing hormonal remedy, chemotherapy, radiation, and bisphosphonate remedy should be nearly covered for BMD loss and cadaverous health conservation conventions (5). It's noteworthy, current recommendations for avoiding the cadaverous complications of BC remedy include acceptable input of Ca and vitamin D, regular weight- bearing exercise, conclusion of smoking, reduction in alcohol input, and bisphosphonate treatment for those set up to be osteoporotic (34).

As a fast and nicely accurate system for constantly covering bone health, we developed vaticination fine formulae for chine and pelvis BMD, which are the spots most susceptible to fracture pitfalls, together with the total BMD of NMBC women. Multiple direct retrogression analysis showed that the covariates age and BMI were significantly associated with BMDspine, BMD pelvis, and BMD total singly (R = 0.99, p<0>

One of the limitations of the present study is the small sample size, being concentrated only on NMBC women who do n’t have serum creatinine lesser than 150 μmol/ L; peptic ulcer; hysterectomy or bilateral oophorectomy; osteoporosis; undressed hypothyreosis; bisphosphonate, calcitonin or peroral steroid remedy; gestation or lactation; and any other malice. therefore, to validate the developed formulae, there's a need to study a bigger population of BC women, conceivably extending and taking into consideration other factors like bone metastasis

 Adjuvant chemotherapy is responsible for dwindling segmental and total BMD in BC postmenopausal women, which can be clinically estimated by the significant changes in both T- and Z- Scores as well as biochemical labels of bone development. The drop in segmental and total BMD was substantially due to significant drop in the situations of peak andS.ALP rather than an increase in CTx- I labels. therefore, measures of BMD and biochemical labels of bone conformation and resorption for BC women before starting any adjuvant chemotherapy is important to assess original status of bone health. We believe, the simple fine formulae developed on base of the two individual variables Age and BMI can be useful for aiding the clinician to constantly cover bone health status of BC cases in analogous conditions, being suitable to manage possible bone losses fleetly and efficiently.

Competing interests

The authors declare that they have no competing interests.

1. Rodriguez-Rodriguez LM, Rodriguez-Rodriguez EM, Oramas-Rodriguez JM, Santolaria-Fernandez F, Llanos M, Cruz J, Martinez A, Gonzalez-Reimers E, Gomez A and Batista N. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer. Breast Cancer Res Treat. 2005; 93:75-83.
2. Rennert G. Breast Cancer. In: Freedman LS, Edwards BK, Ries LAG, Young JL (Eds), Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute. 2006; 73-81.
3. Hadji P, Ziller M, Albert US and Kalder M. Assessment of fracture risk in women with breast cancer using current                    vs                     emerging       guidelines. Br                   J Cancer. 2010; 102:645-50.
4. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD and Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009; 7 Suppl 7:S1-29; quiz S30.
5. Hirbe   A,   Morgan   EA,    Uluckan   O    and   Weilbaecher K. Skeletal complications of   breast   cancer therapies. Clin Cancer Res. 2006; 12:6309s-6314s.
6. Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N and Ohashi Y. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of     N-SAS     BC      04,      the      TEAM      Japan substudy. Oncology. 2010; 79:376-81.
7. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK and Delmas PD. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19:1250-8.
8. Seibel MJ. Biochemical markers of bone turnover: part I:     biochemistry     and     variability. Clin     Biochem Rev. 2005; 26:97-122.
9. Abd-El-Moneim NA, Hussein NG, Morsi MI, El-Kohly ZA, Shaheen NE, Abou-Raoash NM and El-Sayed LH. Effect of two chemotherapeutic regimens on some biochemical and immunological parameters in breast cancer patients. Med. Sci. Res. (England). 1998; 6:301-307.
10. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr., Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R and Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001; 93:979-89.
11. Singletary SE and Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006; 56:37-47; quiz 50- 1.
12. Lewis SM, Bain BJ and Bates I. Dave and Lewis Practical Hematology Textbook. 9th Ed. Harcourt Publisher Ltd., London. 2001; 30-41.
13. Leary NO, Pembroke A and Duggan PF. Single stable reagent (Arsenazo III) for optically robust measurement of calcium in serum and plasma. Clin Chem. 1992; 38:904-8.
14. Lee AJ, Hodges S and Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000; 37:432-46.
15. Ameson WL and Ameson DL. Current Methods for Routine Clinical Laboratory Testing of Vitamin D Levels. Lab. Medicine. 2013; 44:e38-e42.
16. Burtis C, Ashwood E and Bruns D. Tietz Texbook of Clinical Chemistry and Molecular Diagnostics. 4th Ed., Elsevier Saunders Company. St. Louis, 2006; 609-611.
17. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991; 64:154-8.
18. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with   antiresorptive drugs. Osteoporos Int. 2000; 11 Suppl 6:S66-76.
19. Mohamed EI, Maiolo C, Iacopino L, Pepe M, Di Daniele N and De Lorenzo A. The impact of body-weight components on forced spirometry in healthy italians. Lung. 2002; 180:149-59.
20. Casini A, Mohamed EI, Gandin C, Tarantino U, Di Daniele N and De Lorenzo A. Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using        anthropometric        variables. Dig         Liver Dis. 2003; 35:881-7.
21. Mohamed EI and Khalil ES. Bone densitometric analysis in   egyptian   hemodialysis   patients. Int    J    Biomed Sci. 2008; 4:120-4.
22. Mohamed EI,   Mahmoud   GN,   Khalil   GI   and   Sallam SM. Mathematical modeling of segmental and total bone mineral density in Egyptian patients with β- Thalassaemia Major. J. Biophys. Biomed. Sci 2008; 1:69- 74.
23. Lane JM, Serota AC and Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop Clin North Am. 2006; 37:601-9.
24. Mincey BA, Moraghan TJ and Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc. 2000; 75:821-9.
25. Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ and Singer FR. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003; 114:653-9.
26. Wickham R. Osteoporosis related to disease or therapy in patients with cancer. Clin J Oncol Nurs. 2011; 15:E90- E104.
27. Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A and Schwartz A. Strength training stops bone losssurvivors: a randomized, controlled trial. Breast Cancer Res Treat. 2011; 127:447-56.
28. Fontana A and Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000; 88:2952-60.
29. Lipton A, Costa L, Ali S and Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001; 28:54-9.
30. Oremek   GM,   Weis   A,   Sapoutzis   N   and   Sauer-Eppel H. Diagnostic value of bone and tumour markers in patients      with      malignant      diseases. Anticancer Res. 2003; 23:987-90.
31. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999; 45:1359-68.
32. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T and Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional   and   longitudinal    evaluation. Br    J Cancer. 2006; 95:506-14.
33. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350:1655-64.
34. Coleman    RE. Bisphosphonates:                      clinical experience. Oncologist. 2004; 9 Suppl 4:14-27.